Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.

Chang Gon KimMinkyu Jung Hyo Song Kim Choong-Kun LeeHei-Cheul JeungDong-Hoe Koo Woo Kyun Bae Dae Young Zang Bum Jun KimHyunki KimUn-Jung YunJingmin Che Sejung ParkTae Soo KimWoo Sun Kwon Juin Park Sang Woo Cho Chung-Mo Nam Hyun Cheol Chung Sun Young Rha

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

Trastuzumab combined with ramucirumab and paclitaxel showed appreciable efficacy with manageable safety profiles in patients with previously treated HER2-positive G/GEJ cancer.

Keyphrases

epidermal growth factor receptor
tyrosine kinase
papillary thyroid
advanced non small cell lung cancer
squamous cell
endothelial cells
childhood cancer
induced pluripotent stem cells